News 
Market Data 
Discover
cars100cars
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
| Ticker | Board | News | Price | Change | Chg% | Added | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| ATHXQ | Athersys Inc | 0.0036 | -0.0008 | -18.18% | 09/12/2016 | |||||
|
My ATHXQ Pitch: Uniform stem cell treatment, off-the-shelf product, usable with all patients. Very promising research. Effectiveness in treating stroke patients within the first 36 hrs of stroke. Improved outcomes are significant. FDA study progressing. Major Japanese partner with study there starting.
|
||||||||||
| CERS | Cerus Corporation | 1.75 | 0.0 | 0.00% | 08/29/2016 | |||||
|
My CERS Pitch: FDA approved Intercept blood supply treatment kills Zika, other viruses, Hep C and B. American Red Cross blood centers just began ordering Summer 2016. FDA recommends use for all Zika high risk states.
|
||||||||||
| NEO | NeoGenomics Inc | 0 | 0 | 0.00% | 08/29/2016 | |||||
|
My NEO Pitch: Fast growing genomic testing lab company. Accelerating sales. Bought GE unit in 2015. At current rate, could reach $500 million in sales by 2017.
|
||||||||||
| MTNB | Matinas Biopharma Holdings Inc | 0.1835 | 0.0 | 0.00% | 08/29/2016 | |||||
|
My MTNB Pitch: Novel nano encapsulation delivery system that allows targeted dose of very small amounts of highly potent drugs that otherwise can't be administered safely or conveniently. Targeting drug resistant infections that don't respond any longer to antibiotics, yet are known to respond to stronger drugs.
|
||||||||||
| AGEN | Agenus Inc | 12.76 | 0.0 | 0.00% | 08/29/2016 | |||||
|
My AGEN Pitch: Big deal with Merck. Very promising oncology drug platform.
|
||||||||||
| CTSO | CytoSorbents Corporation | 0.806 | 0.0 | 0.00% | 08/29/2016 | |||||
|
My CTSO Pitch: High end medical disposable product that helps docs control inflammation. Approved in 32 countries. 14,000 safe human treatments. FDA evaluating for cardiac surgery with pivotal study likely in 2017. One of the few methods available for helping docs gets control of sepsis patients in the ICU.
|
||||||||||
| CRMD | CorMedix Inc | 0 | 0 | 0.00% | 07/15/2016 | |||||
|
My CRMD Pitch: FDA approval likely. Current CRMD trial interim data excellent. Primary product, an anti infective, reduces significantly infections from catheters.
|
||||||||||
